PATIENTS AND METHODS
Since November 1988, seven children with SCA, aged 2 to 14 years, were selected for BMT in our institution and were treated according to a previously described protocol! Approval was obtained from the Institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki.
The three oldest patients (aged 10, 1 1, and 14 years) were carefully investigated for splenic function before and after BMT. Table 1 summarizes the clinical symptoms presented by the three patients before BMT.
May-Grunwald-Giemsa-stained blood films were examined for the presence of Howell-Jolly bodies before and after BMT. The technetium 99m (99mTc) sulfur colloid was prepared with particles of 0. 
RESULTS
All three patients engrafted successfully with acceptable early and late toxicity ( Table 2 ). The actual follow-up ranges from 8 to 43 months. All three patients have now hemoglobin levels above 10 g/dL with electrophoretic pattern of donor type. Chromosome studies were noninformative because donor and recipient were of the same sex in each case. Since the time of transplantation, all three patients remain free of new SCA manifestations. Patient 1 developed a limited de novo chronic graft versus host disease (GVHD) that promptly responded to immunosuppressive therapy.
Before BMT, no patient had a palpable spleen. Repeated blood smear screenings in all three patients disclosed the presence of numerous Howell-Jolly bodies as well as sickled cells (Fig 1 A) . Hepatosplenic radionuclide "Tc scintigraphy did not demonstrate splenic uptake (Fig 2A) . Furthermore, prior to BMT, patients 2 and 3, suffering from symptomatic vesicular lithiasis, underwent surgery for cholecystectomy. In both cases, the spleen had a fibrosislike appearance at laparotomy.
A careful screening of multiple blood smears 3, 6, and 12 months after BMT did not show the presence of Howell-Jolly bodies (Fig IB) . In patients 1 and 2, "Tc hepatosplenic scintigraphy performed 1 and 1.5 years after BMT showed the presence of normal size splenic tissue (Fig 2C) .
In patient 3, a hepatosplenic scintigraphy performed 3 months after BMT already showed the presence of splenic uptake (Fig 2B) .
DISCUSSION
As previously reported by our group, we confirm that BMT in SCA is feasible, with a high cure rate.6 We and others did not see any mortality events related to the transplantation However, morbidity events such as opportunistic infections, hemorrhage, GVHD, graft rejection, lung fibrosis, infertility, or secondary tumors have to be expected. Long-term follow-up of our successful grafted patients shows that they have a stable hemoglobin level and do not suffer from new SCA-related events.
Among the seven grafted patients, none developed acute GVHD, one developed a chronic GVHD, and two suffered from graft rejection. However, it remains to be determined if BMT can restore or improve the functions of organs severely damaged by the underlying disease. In this context, we studied splenic function in three patients.
Functional asplenia is defined as impaired splenic reticuloendothelial function. This inability to clear particules or microorganisms from blood develops early in the life of patients with SCA? Consequently, these patients are prone to develop microbial infections with a well-known increased risk of pneumococcal sepsis." Functional asplenia is classically defined by (1) the presence of Howell-Jolly bodies in circulating red cells and (2) the absence of reticuloendothelial splenic function, demonstrated by the disappearance of wmTc splenic uptake, even in the presence of a palpable spleen.'2 It was well demonstrated that functional asplenia may reverse after red blood cell (RBC) transfusion in young patients with palpable spleen. This reversible functional asplenia is explained by the fact that blood having a high viscosity bypasses the reticuloendothelial tissue of the spleen through intrasplenic shunts. However, by the age of 7, patients with SCA are considered as permanently asplenic despite RBC transf~sions.'~ At this age, most patients have a small fibrotic For personal use only. on October 23, 2017. by guest www.bloodjournal.org From spleen (as seen at laparotomy in patients two and three). This "autosplenectomy" results from progressive vascular occlusion and infarction, and transfusion is not able to restore any more splenic function in this ~ituati0n.l~ We demonstrate here that, after BMT, permanent perfusion of the spleen with rheologically normal blood restores its size and its reticuloendothelial function. The deficit is corrected early in the course of the BMT because patient 3 had functional splenic tissue detectable 3 months after BMT. Patients 1 and 2 were first tested 12 and 18 months after BMT and were found to have functional splenic tissue, as measured by 99mTc uptake, with normal spleen size. Thus, in this study, we show for the first time that "permanent" organ damages resulting from vaso-occlusion can in fact be reversible after BMT in patients with SCA.
Careful investigation before and after BMT in the next SCA grafted patients should answer the question if organ damage secondary to ischemic vascular lesions in the eyes, kidney, brain, and lung is also reversible.
The results of these studies will be of critical importance to support the eventual role of BMT as a curative treatment in patients with SCA. For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
